Cabiralizumab: Completed Ph I/II enrollment

Five Prime completed enrollment of 30 patients in the Phase II portion of an open-label, international Phase I/II trial evaluating IV cabiralizumab every 2 weeks. The trial enrolled 45 patients in tot...